Relapse prevention planning is about preparing for difficult moments before they happen. Recovery can become more challenging when cravings, stress, emotional pressure, loneliness or familiar triggers return, so having a clear plan can make it easier to recognise risk early and respond before substance use happens.
A strong relapse prevention plan looks at the situations that make recovery more difficult, the warning signs that may appear before a relapse, the people who can offer support, and the practical actions that can be taken when cravings or emotional pressure begin to increase.
The goal is not simply to avoid drugs or alcohol from one day to the next. It is to build a recovery routine that becomes more stable, more predictable and easier to protect. When relapse prevention techniques are practiced regularly, they can help a person recognise triggers earlier, respond to cravings more effectively, use coping strategies more consistently and stay connected with treatment and support.
In this guide, you will learn how to prevent relapse, how to create a practical relapse prevention plan, how to recognise early warning signs, and what to do when recovery begins to feel less stable. We will also explain why overdose prevention can be an important part of recovery planning, especially after a period of abstinence.
When these techniques are applied consistently, recovery can become less reactive and more intentional. Instead of making important decisions in moments of stress or craving, you can prepare your response in advance and build habits that support longer-term stability.
Relapse prevention planning is a structured process of identifying personal triggers, early warning signs and high-risk situations, then deciding in advance which coping strategies, treatment and sources of support can be used when the risk of returning to substance use begins to increase.
In simple terms, a relapse prevention plan answers one important question: “What will I do when recovery becomes difficult?”
Recovery does not become difficult in exactly the same way for everyone. One person may experience stronger cravings during periods of stress or relationship conflict. Another may be affected by loneliness, boredom, certain people, familiar places, difficult emotions or memories connected with previous substance use.
This is why effective relapse prevention planning should be personal. Instead of relying on a general intention such as “I will not use again,” the person learns to recognise their own pattern of risk and prepares specific responses that can be used when that pattern begins to appear.
A relapse prevention plan changes recovery from “I hope I can handle it when it happens” to “I already know what I am going to do when it happens.”
Modern relapse prevention has been strongly influenced by the work of G. Alan Marlatt, PhD, a University of Washington psychologist and internationally recognised researcher in addictive behaviour, together with psychologist Judith R. Gordon.
Their landmark 1985 book, Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, helped establish a cognitive-behavioral approach to relapse prevention. Rather than viewing relapse simply as evidence that treatment had failed, their work examined the situations and processes that can make a return to substance use more likely.
The model places particular importance on high-risk situations, coping skills, cravings, expectations and self-efficacy — a person’s confidence in their ability to respond effectively when difficult situations arise.
“Changing a habit is a process of skill acquisition rather than a test of one’s willpower.”
— Larimer, Palmer & Marlatt, Relapse Prevention: An Overview of Marlatt’s Cognitive-Behavioral Model
This principle is particularly important in addiction recovery. Relapse prevention is not simply about trying harder to resist alcohol or drugs. It involves learning and repeatedly practising skills that make it easier to recognise risk, manage difficult situations and ask for support before the situation becomes more difficult to control.
Marlatt’s model remains influential today. Modern clinical guidance continues to recommend many of the same practical principles: recognising early warning signs, anticipating emotional and situational triggers, identifying sources of support and deciding in advance what actions should be taken when risk begins to increase.
The U.S. Agency for Healthcare Research and Quality recommends including a prevention plan in treatment and working with patients to identify warning signs, emotional or situational triggers and concrete steps they can take if their condition begins to worsen.
A useful plan should turn general recovery goals into specific actions. It should help the person recognise what increases their risk, what changes may signal that recovery is becoming less stable and what can be done about it.
Situations, people, emotions, environments or experiences that have previously increased cravings or the desire to use alcohol or drugs.
Changes in thoughts, emotions, behaviour, sleep, relationships or recovery routines that may indicate that relapse risk is increasing.
Specific actions that can be used when cravings, stress or other high-risk situations begin to appear.
Family, friends, counselors, peer-support contacts or treatment professionals who can be contacted when additional help is needed.
Counseling, appointments, medication when clinically appropriate, recovery support and daily routines that help maintain stability.
Clear steps for seeking help quickly, reducing further risk and reconnecting with treatment rather than allowing one episode of use to develop into a longer return to substance use.
One of the most useful principles of relapse prevention is that the best opportunity to intervene may come before substance use actually occurs.
Relapse can develop gradually. Stress may increase. Sleep can deteriorate. Counseling sessions may start being missed. A person may become more isolated, begin thinking about substances more frequently or return to people and environments associated with previous use.
These changes can act as early warning signs. Recognising them gives the person an opportunity to respond while there are still many options available — contacting a counselor, speaking to someone in their support network, changing the environment, using a practiced coping strategy or seeking additional treatment support.
This is why relapse prevention approaches focus so strongly on identifying high-risk situations and developing coping responses. The purpose is not to create a life in which difficult situations never occur. The purpose is to become better prepared for them.
Relapse prevention planning is not a one-time exercise. The risks a person faces during the first weeks of recovery may be very different from the challenges they experience six months or a year later.
Early recovery may focus heavily on managing cravings, avoiding certain environments and establishing treatment and support. Later challenges may involve work stress, relationships, boredom, social events, confidence or even the belief that substance use can now be safely controlled.
Current clinical guidance also recognises that stressors, coping strategies and recovery needs change over time. For this reason, a relapse prevention plan should be reviewed and adjusted as the person’s circumstances change.
The next step is understanding why relapse happens. Once we understand the role of cravings, stress, triggers, learned behaviour and the brain’s response to addiction, it becomes much easier to understand why particular relapse prevention strategies can work.
A written relapse prevention plan turns good intentions into clear actions. Instead of trying to decide what to do while stressed, emotionally overwhelmed or experiencing strong cravings, the person already has a response prepared.
This can make daily recovery feel more organised and predictable. Triggers may be noticed earlier, difficult situations can be handled with less panic, and asking for support can become a normal part of the recovery routine rather than something that only happens during a crisis.
Recognise changes in mood, behaviour and cravings before they become more difficult to manage.
Use a response that has already been planned instead of relying on judgement in a high-risk moment.
Build regular habits around treatment, support, sleep, coping strategies and avoiding known risks.
Used consistently, a written plan can help recovery become less reactive and more intentional. Over time, the person may spend less energy simply trying to avoid relapse and more energy building a normal daily life around work, family, relationships, health and long-term recovery.
This educational presentation explains important relapse prevention principles, including warning signs, high-risk situations and concepts associated with the work of G. Alan Marlatt and Terrence Gorski.
Educational presentation discussing relapse-prevention principles associated with G. Alan Marlatt and Terrence Gorski.
The words lapse, relapse and recurrence of use are sometimes used interchangeably, but understanding the difference can change how a person responds when something goes wrong in recovery.
Most importantly, one episode of substance use does not automatically mean that all recovery progress has been lost. What happens after that episode can be extremely important.
A lapse generally describes a single episode or short return to alcohol or drug use after a period of abstinence, followed by an attempt to return to the recovery plan.
In many relapse-prevention models, relapse describes more than one isolated incident. It can involve a developing process in which substance use becomes repeated and previous patterns of behaviour begin to return.
Modern healthcare guidance increasingly uses terms such as “return to use” or “recurrence of use” to describe substance use after a period of improvement or remission.
Imagine that someone has been in recovery for six months and uses a substance once. If they think, “I have relapsed, so everything I achieved is gone,” they may be more likely to give up on the recovery plan.
A more useful response is: “Something increased my risk. I need to understand what happened and act now.”
That may mean contacting a counselor, telling someone in the support network, reviewing what triggered the episode, adjusting treatment or temporarily avoiding a high-risk environment.
In other words, a lapse can become information. It can reveal a weakness in the current relapse prevention plan that can be corrected before the situation becomes more serious.
The more useful question is: “What happens next, and how quickly can recovery support be strengthened?”
Terminology note: This guide continues to use the term “relapse” because it remains widely recognised and commonly searched by people looking for addiction recovery information. In healthcare settings, you may increasingly see “return to use” or “recurrence of use” used instead.
Relapse rarely happens for just one reason. It is usually the result of several factors coming together — changes in the brain’s reward and learning systems, cravings, emotional stress, exposure to familiar triggers and situations where the ability to make calm decisions becomes more difficult.
During addiction, the brain can learn powerful associations between a substance and certain people, places, emotions and experiences. Even after substance use stops, some of these learned associations can remain and may trigger cravings when the person encounters them again.
Stress can add another layer of risk. Research has linked stress and negative emotional states with stronger cravings and a greater risk of returning to substance use. This helps explain why relapse prevention needs to address more than simply avoiding alcohol or drugs.
Addiction can change how the brain learns about reward and gives importance to substance-related cues, allowing cravings to reappear even after a period of abstinence.
Stress, emotions, people, places and situations previously connected with substance use can become powerful triggers during recovery.
Relapse is not simply evidence of weak motivation. Addiction can affect decision-making, habits and responses to reward and stress, which is why treatment, coping skills and preparation can be so important.
The National Institute on Drug Abuse describes addiction as a medical disorder that affects the brain and behaviour rather than a failure of willpower. Research from NIAAA also shows how reward, stress and executive-control systems interact during addiction and recovery.
Understanding these three areas makes it easier to see where relapse risk comes from — and where a prevention plan can intervene. We will look at each of them next.
One reason relapse can feel confusing is that a person may genuinely want to stay in recovery while another part of the brain reacts strongly to a substance-related cue. Understanding this does not remove personal responsibility — but it helps explain why cravings can sometimes appear so quickly and feel so powerful.
The brain naturally learns which experiences are important and worth repeating. Dopamine plays an important role in this learning and motivation system. It helps the brain remember that something significant happened and strengthens the connection between an experience and the circumstances surrounding it.
Drugs and alcohol can strongly engage these reward and learning systems. With repeated use, the brain may begin connecting the substance not only with its effects but also with the people, places, smells, music, emotions, routines and situations that were repeatedly present when it was used.
The brain can learn: “When this situation appears, expect the substance.”
Later, the situation itself may activate desire or craving — even when the person consciously does not want to use.
For example, someone may feel relatively comfortable for weeks and then suddenly experience a strong craving after driving past an old neighbourhood, hearing a particular song, receiving a message from someone they previously used with or experiencing an emotion that was repeatedly followed by substance use.
This does not necessarily mean that recovery is failing. It may mean that the brain has recognised an old learned cue.
This is one reason cravings should be treated as signals to respond to rather than instructions that must be followed. A craving can rise, change and eventually pass. Learning what activates it gives the person an opportunity to prepare a different response.
Research: The U.S. National Institute on Drug Abuse explains that dopamine is particularly important in reinforcing behaviour and helping the brain learn associations between drug use and surrounding cues. Read the NIDA overview →
Not every relapse begins with a desire to feel good. Sometimes the stronger motivation is simply the desire to stop feeling bad.
Stress, anxiety, anger, loneliness, relationship problems, physical discomfort, poor sleep or financial pressure can make recovery more difficult. If alcohol or drugs were repeatedly used in the past to escape these feelings, the brain may have learned an association: distress → substance → temporary relief.
That association can become especially important during recovery. When the same emotional state returns, thoughts about the substance may return with it — not necessarily because the person wants their old life back, but because the brain remembers a previously learned method of obtaining relief.
Environment works in a similar way. A bar, bedroom, payday, weekend, certain group of friends or even a particular time of day can become associated with previous substance use. These are often called triggers or conditioned cues.
The useful part of understanding this is that a trigger is not the same thing as a relapse. A trigger is information. Once a person knows what tends to activate cravings, the environment can be changed, exposure can sometimes be avoided, support can be contacted earlier and a planned coping response can be used.
Answers to these questions become extremely valuable when building a relapse prevention plan because they turn a vague risk into something that can be recognised and managed.
Research: A 2024 scientific review describes how repeated and chronic stress can disrupt normal stress responses and is associated with maladaptive coping, increased craving and greater relapse risk in substance use disorders. Read the research review →
Wanting recovery matters. Motivation matters. Personal decisions matter. But expecting willpower to carry the entire recovery process can place a person under unnecessary pressure.
Addiction involves systems responsible for reward, learning, stress, habits, impulse control and decision-making. During a calm moment, someone may clearly understand why they do not want to use again. During intense craving, emotional distress or exposure to a powerful trigger, making the same decision may become considerably harder.
The prefrontal cortex helps with functions such as planning, controlling impulses, evaluating consequences and making decisions. Research on addiction shows that these executive-control processes can become disrupted, while drug-related cues and stress may simultaneously become unusually important.
Recovery becomes harder when the brain’s “go toward the reward” signal becomes very loud at the same time that the system responsible for “stop, think and consider the consequences” is under stress.
This helps explain an experience many people in recovery find difficult to understand: “I knew exactly why I shouldn’t do it, but in that moment I still wanted to.”
The solution is not to assume that the person has no control. The better approach is to avoid making recovery depend on one moment of self-control.
Know the trigger before it happens.
Decide your response while thinking clearly.
Know exactly who you will contact.
Act when the first warning signs appear.
Counseling, behavioral strategies, peer and family support, changes to the environment, treatment of co-occurring conditions and medications when clinically appropriate can all provide additional layers of protection.
The objective is to create a recovery system in which the person does not need to win the same battle through willpower every day. Over time, healthier routines and coping responses can become more familiar, while the person’s understanding of their own triggers becomes stronger.
Cravings are not proof that you want to return to addiction. Triggers are not proof that relapse is inevitable. Stress is not failure.
They are signals that tell you when your relapse prevention plan needs to become active.
Research: NIDA describes addiction as a medical disorder that affects the brain and behaviour, replacing the older idea that addiction is simply caused by poor character or lack of willpower. National Institute on Drug Abuse →
Relapse does not always begin with the moment someone drinks alcohol or uses a drug. In many cases, changes in emotions, thoughts and everyday behaviour can appear earlier. Learning to recognise these warning signs can create valuable time to respond before the situation becomes more difficult.
This is important because the earlier a change is noticed, the more options a person may have. They can speak with a counselor, contact someone in their support network, change their environment, strengthen their daily routine or review their relapse prevention plan before cravings or thoughts about using become more intense.
The purpose of watching for warning signs is not to predict relapse with certainty. It is to recognise when recovery may be becoming less stable and take action while the problem is still easier to manage.
Warning signs are different for every person. A difficult day, poor night’s sleep or argument does not automatically mean someone is going to relapse. What matters more is noticing patterns and changes from the person’s normal recovery routine — particularly when several warning signs begin appearing together.
Changes such as increasing anxiety, anger, isolation, emotional distress or neglecting basic self-care may indicate that recovery is becoming harder to maintain.
Thoughts about previous substance use may become more frequent, cravings may increase, or a person may begin remembering the perceived benefits of using while minimising the consequences.
Changes may become visible in daily life — missing treatment, withdrawing from support, abandoning healthy routines or reconnecting with people and environments associated with previous substance use.
Imagine someone normally attends counseling, sleeps reasonably well, speaks openly with family and follows a regular recovery routine. Over several weeks they begin sleeping less, isolating themselves, missing appointments and thinking more often about using.
None of these changes alone proves that relapse will happen. Together, however, they can signal that additional support may be needed now rather than after substance use has already occurred.
Over time, recognising these patterns can help a person understand their own recovery much better. Instead of only reacting when cravings become overwhelming, they may begin noticing the smaller changes that happen days or even weeks earlier.
That is one of the main purposes of a relapse prevention plan: to turn early warning signs into a reason to act, rather than waiting for a crisis.
Clinical guidance: The U.S. Agency for Healthcare Research and Quality recommends helping people identify early warning signs and emotional or situational triggers as part of a prevention plan. SAMHSA guidance also describes emotional, mental and behavioral warning signs that can indicate additional recovery support may be needed. Read the AHRQ guidance →
Emotional warning signs can be easy to miss because the person may not be thinking about using alcohol or drugs at all. Instead, the first change may be in how they feel, communicate and take care of themselves.
Increasing anxiety, irritability, anger, guilt, shame, loneliness or emotional exhaustion can place additional pressure on recovery. Some people begin withdrawing from others, stop talking openly about how they feel or start keeping problems to themselves.
You stop answering calls, seeing supportive people or participating in recovery activities.
You say that everything is fine while stress, anger, anxiety or sadness continues to build.
Sleep, eating, exercise, hygiene or normal routines become less important.
Small problems begin producing unusually strong anger, frustration, anxiety or hopelessness.
One bad day is not necessarily a warning of relapse. The more useful question is: “Am I behaving differently from the way I normally behave when my recovery is going well?”
Mental warning signs often become more noticeable when the substance starts taking up more space in the person’s thoughts. There may be an internal conflict: one part of the person wants to protect recovery while another begins considering whether using again might be possible.
This can start subtly. A person may remember the enjoyable parts of previous substance use while giving less attention to the problems it caused. They may begin bargaining with themselves or imagining circumstances in which they could use “just once” or somehow control it differently this time.
You remember the excitement or relief while temporarily overlooking the consequences.
Thoughts appear such as “only once,” “only on holiday,” or “maybe I can control it now.”
You notice that alcohol or drugs are entering your thoughts more often than before.
You think about where you could use, who you could contact or how you could hide it.
There is an important difference between having a thought about using and beginning to prepare for using. An unwanted craving can occur during recovery. Risk becomes more concerning when the person starts feeding the thought, bargaining with it or making practical plans around it.
Lower concern: “I suddenly thought about drinking. I don’t want to act on it, so I’m going to call someone.”
Higher concern: “Maybe I could drink on Saturday. Nobody needs to know. I could probably keep it under control.”
Behavioral warning signs are often the easiest for other people to see because they appear in what the person actually starts doing differently.
A recovery routine that was previously consistent may begin to weaken. Counseling sessions may be missed. Support calls stop. Sleep becomes irregular. Healthy boundaries disappear. The person may start spending time with people or visiting places strongly associated with previous substance use.
Counseling, meetings, appointments or conversations with supportive people become less frequent.
Sleep, meals, exercise, work routines or other stabilising habits become increasingly irregular.
You begin visiting places or reconnecting with people strongly associated with previous substance use.
You begin hiding where you are going, who you are seeing or what you are thinking about.
The most useful way to recognise behavioral warning signs is to compare today’s behaviour with the behaviour that normally supports your recovery.
Attending treatment, staying connected, sleeping reasonably well, maintaining boundaries and being open about difficulties.
Missing support, isolating, abandoning routines, increasing secrecy and moving back toward people or situations connected with previous use.
A warning sign does not mean relapse is inevitable. Everyone experiences stress, difficult emotions and disrupted routines occasionally.
Pay closer attention when you notice several changes appearing together, becoming stronger or continuing instead of resolving. That is a good time to use the relapse prevention plan, reconnect with support or speak with a treatment professional.
Clinical source: SAMHSA’s Counseling Approaches to Promote Recovery From Problematic Substance Use and Related Issues (TIP 65) describes emotional, mental and behavioral warning signs of recurrence and emphasizes that recognising them can help identify when additional recovery support may be needed. Read the SAMHSA guidance →
This may be one of the most practical sections in this entire guide because you cannot prepare for a trigger that you do not recognise. The better you understand what increases your personal risk, the earlier you can act instead of waiting until a craving becomes difficult to manage.
A relapse trigger is something that increases the desire, thought or impulse to return to substance use. It can come from outside — such as a person, place, social situation or seeing a substance — or from inside, such as stress, loneliness, anger, anxiety, boredom or a difficult memory.
Importantly, experiencing a trigger does not mean that relapse is inevitable. A trigger is better understood as a signal: “My risk has increased, so this is the moment to use my recovery plan.”
When you can identify your own triggers, recovery becomes less about being surprised by cravings and more about recognising what is happening early enough to respond.
Research has shown that some of the most important relapse triggers include stress, environmental cues connected with previous substance use and exposure to alcohol or drugs. These cues can become strongly learned over time, which is why a familiar place, person, emotion or situation can sometimes produce a craving even after a long period without using.
The purpose of learning about triggers is therefore not to create a life in which every uncomfortable situation must be avoided. That would be unrealistic. The goal is to understand which situations require more preparation, stronger boundaries or additional support.
As you read the next sections, do not only ask “Is this a common relapse trigger?” Ask: “Does this happen to me, and what usually happens next?”
You may discover that your strongest trigger is not the substance itself. It could be stress after work, an argument with a partner, being paid, feeling lonely at night, seeing particular friends, celebrating, boredom or simply returning to an environment strongly connected with previous use.
By the end of the following sections, you should be able to identify your most important personal triggers, understand why they affect you and begin deciding what you will do differently when they appear.
That information will later become one of the most important parts of your written relapse prevention plan.
Research: The National Institute on Drug Abuse identifies stress, cues linked with previous drug experiences — including people, places, things and moods — and exposure to drugs as common triggers for relapse. Current AHRQ guidance also recommends identifying individual life stressors and triggers when developing a prevention plan. NIDA: Drugs, Brains, and Behavior →
Stress is one of the most important relapse triggers to understand because it can change how you feel, what you think about and how you make decisions. The trigger may be a major event, such as relationship problems, financial difficulties or bereavement, but it can also be smaller pressures building up day after day.
If alcohol or drugs were repeatedly used in the past to relax, escape, sleep, feel more confident or temporarily reduce emotional pain, the brain may have learned an association between feeling stressed and seeking the substance for relief.
The goal is not to eliminate stress from life. That is impossible. The goal is to recognise when pressure is increasing and respond before the old coping method becomes the easiest option in your mind.
Sometimes a craving appears unexpectedly simply because you are somewhere — or with someone — strongly connected with your previous substance use.
The brain can learn associations between substance use and the environment surrounding it. This may include particular friends, houses, neighbourhoods, bars, music, smells, driving routes, weekends, payday or even a particular time of night.
These are often called conditioned cues. Encountering one of them can activate memories, expectations or cravings even when you had not been thinking about using minutes earlier.
You feel comfortable throughout the day. Later, you meet someone you previously used drugs with and suddenly begin thinking about using.
That does not mean the person automatically caused a relapse. The situation may have activated a strong association learned through previous experience.
Especially in earlier recovery, avoiding certain situations may be sensible. This is not weakness. It is risk management. Recovery does not require repeatedly testing yourself against your strongest triggers simply to prove that you can resist them.
For some people, using a different substance can make returning to their previous substance more likely — even when that was not the original intention.
Alcohol is a common example because intoxication can affect judgment and inhibition. A boundary that feels completely clear while sober can become easier to negotiate after drinking.
While sober: “I don’t want to contact that person or use that drug again.”
After becoming intoxicated: “Maybe once would be fine. I could probably control it now.”
Another substance may also return someone to the same people, places, routines and behaviours that were previously connected with addiction.
This is highly individual. The important question is not whether another person can safely drink or use a particular substance. It is whether your own history shows that one substance tends to lead toward another.
Recovery can become more vulnerable when someone gradually disconnects from the people and structures that were helping them remain stable. This can be particularly difficult to notice because it often happens slowly.
It may begin with one missed counseling appointment, fewer telephone calls, stopping a recovery meeting or deciding that support is no longer necessary because things are going well.
None of these events automatically causes relapse. The concern is when several protective parts of recovery begin disappearing at the same time.
Someone can notice when you are struggling.
You have somewhere to discuss cravings honestly.
Risky decisions can be discussed before acting on them.
You remain connected with your recovery goals.
Problems can remain hidden for longer.
Cravings may be dealt with entirely alone.
There is less outside perspective when thinking changes.
Returning to old relationships can become easier.
Being alone is not the same as being isolated.
Spending time alone can be healthy. Isolation becomes concerning when you begin withdrawing from support precisely when you are struggling and stop allowing other people to know what is happening.
Poor sleep, anxiety and emotional distress deserve special attention because they can make several other relapse triggers harder to manage at the same time.
When you are exhausted, everyday problems can feel larger. Concentration can become more difficult, patience may decrease and coping strategies that normally work can become harder to use. If this happens alongside anxiety, sadness, anger or persistent emotional distress, the desire for immediate relief may become stronger.
Sleep and substance use also have a complicated two-way relationship. Substance use and withdrawal can disturb sleep, while ongoing sleep problems are common during recovery. Research increasingly suggests that significant sleep disturbance may also contribute to vulnerability to craving and recurrence of substance use.
The lesson is not that one sleepless night will cause relapse. Instead, look for a persistent change from your normal level of functioning, especially when poor sleep appears together with stronger cravings, anxiety, isolation or difficulty following your normal recovery routine.
Recent research continues to identify sleep disturbance as an important and potentially modifiable issue in substance-use recovery. Sleep problems are common across several substance-use disorders and may continue beyond the initial period of abstinence.
Persistent anxiety, depression, severe insomnia or other emotional difficulties should not simply be treated as something a person must “push through.” Discussing them with a healthcare or mental-health professional may allow them to be assessed and treated as part of the overall recovery plan.
Relapse triggers often combine rather than appear separately.
Poor sleep can make stress harder to manage. Stress can lead to isolation. Isolation can bring old thoughts back. An old friend or environment can then activate a craving, while alcohol or another substance can make a risky decision easier.
Learning your own sequence gives you something extremely valuable: an earlier place to interrupt it.
Up to this point, we have focused on understanding why relapse happens, how triggers develop and which warning signs may appear before substance use returns. Now we move into the most practical part of this guide: what can actually be done to reduce relapse risk.
There is no single technique that prevents every relapse. The strongest approach usually combines several layers of protection: recognising personal triggers, having a plan for cravings, remaining engaged with treatment, using counseling and behavioral strategies, considering medication when appropriate, and staying connected with people who support recovery.
The goal is to make recovery less dependent on one difficult decision in one difficult moment. Each strategy below removes some pressure from willpower and gives the person another way to respond when risk begins to rise.
Effective relapse prevention is not one barrier. It is a system of barriers.
If one layer becomes weaker — for example, stress increases or a trigger appears — other layers such as treatment, medication, counseling, support and a prepared craving-response plan can still help protect recovery.
Learn which emotions, people, environments and situations consistently increase your risk so that you can respond earlier.
Decide in advance what you will do during a strong craving instead of trying to invent a solution while the craving is already intense.
Recovery support is often most useful before a crisis develops. Staying engaged can help identify changes before they become more serious.
Counseling can help turn knowledge about triggers into practical coping skills, healthier routines and different responses to stress.
For some substance-use disorders, medication can reduce craving, reinforce abstinence or change the effects a substance produces, adding another layer to behavioral treatment.
Having people who know the recovery plan makes it easier to ask for help early rather than trying to manage every difficult moment alone.
One of the most interesting developments in relapse prevention is the ability to combine psychological recovery strategies with medication.
Naltrexone is an opioid-receptor antagonist. For opioid use disorder, it blocks opioid receptors while the medication is active, reducing or blocking the rewarding effects of opioids. SAMHSA also notes that naltrexone can reduce and suppress opioid cravings in appropriate patients.
This does not erase triggers or make counseling unnecessary. Instead, it can change the environment in which recovery work takes place.
A trigger may still be recognised, but knowing that opioids are pharmacologically blocked can remove part of the expected reward associated with acting on that trigger.
Naltrexone can reduce opioid craving in some patients, potentially making it easier to apply coping strategies rather than fighting an intense urge alone.
When the immediate pressure to obtain a substance is reduced, some people may find it easier to concentrate on relationships, routines, thinking patterns and the underlying problems that counseling is designed to address.
Sustained-release formulations are designed to maintain medication exposure without requiring a tablet to be chosen every day, which can address one of the adherence problems associated with oral naltrexone.
This is an important concept: medication does not replace relapse-prevention skills — it may make those skills easier to use.
A person can still learn their triggers, attend counseling, build accountability, improve sleep, repair relationships and develop new coping strategies. Medication can provide an additional biological layer alongside that work rather than asking the individual to rely on willpower alone.
We will look more closely at long-acting naltrexone, how opioid-receptor blockade works, what the research shows about sustained-release formulations, where the evidence is strongest, and how medication can be integrated with counseling and long-term relapse prevention.
We will now take these prevention strategies one at a time and turn them into actions that can be used in everyday recovery.
Knowing why relapse happens is only useful if that knowledge changes what you do before a difficult moment arrives. The next step is to turn relapse prevention into a daily system: recognise risk early, know how to respond to cravings, stay connected with treatment and make sure support is available when your judgement is under pressure.
These strategies work together. You do not need one perfect technique. You need several layers of protection so that if one part of recovery becomes weaker, another part can still support you.
Start by identifying what consistently changes your thinking about alcohol or drugs. General trigger lists can help, but your own history gives you the most useful information.
Look back at previous cravings, lapses or periods when recovery became difficult. What happened during the hours or days beforehand? Think about stress, emotions, people, places, money, sleep, arguments, loneliness and changes in your normal routine.
For the next week, write down four things whenever a noticeable craving appears:
Where were you and what was happening?
Stress, anger, boredom, anxiety, loneliness?
What did your mind tell you about using?
Record what reduced the craving or stopped it progressing.
After several entries, patterns often become easier to see. Those patterns should become part of your written relapse prevention plan.
A craving-response plan removes one dangerous question from a difficult moment: “What should I do now?”
Decide the answer while you are thinking clearly. Your plan should be short enough that you can follow it even when you are stressed or distracted.
If I experience a strong craving, I will:
The purpose is not necessarily to make every craving disappear immediately. The goal is to create distance between the urge and the action.
Treatment is not only something to use when recovery is going badly. One of its most useful roles is helping prevent problems from becoming serious in the first place.
A common mistake is reducing support as soon as life starts improving. But feeling better may be evidence that the treatment and recovery structure are working — not necessarily evidence that they are no longer needed.
AHRQ recommends updating relapse-prevention plans throughout recovery because triggers, circumstances and treatment needs change over time.
Counseling is where many of the ideas in this article can become actual skills. It can help you recognise thinking patterns, practise responses to triggers, improve emotional regulation and understand why certain situations continue to have so much power.
Recognise thoughts and situations that increase risk and practise alternative responses.
Reconnect with your personal reasons for recovery when motivation becomes weaker.
Deal with relationships, work, money and other pressures before they become triggers.
Practise what to do before, during and after a high-risk situation.
SAMHSA specifically identifies relapse-prevention skills, cognitive-behavioral techniques and Motivational Interviewing among counseling approaches that may support treatment and recovery.
Bring your trigger log to counseling. Instead of only discussing how the week felt, choose one real high-risk situation and work out exactly how you could respond differently next time.
For some substance-use disorders, medication can add another layer of protection to the behavioral strategies described above.
For opioid use disorder, the FDA recognises three medications: methadone, buprenorphine and naltrexone. They work differently, and there is no single medication that is best for every patient.
Naltrexone is also used for alcohol use disorder in approved formulations. The correct treatment should depend on medical assessment, the substance involved, previous treatment, recovery goals and the patient’s individual risks.
A useful way to think about medication is that it can reduce one source of pressure while counseling, routines, relationships and coping skills are being strengthened.
A relapse prevention plan becomes much stronger when at least one other person knows what is in it.
Accountability is not about somebody controlling you. It means having someone who can recognise changes, listen when cravings increase and help you act before an impulsive decision becomes harder to reverse.
Identify at least two people:
Tell them what you need from them before a crisis happens.
“My cravings have increased and I don’t want to manage this alone. Can you stay in contact with me while I get back to my recovery plan?”
For appropriately selected people recovering from opioid use disorder, long-acting naltrexone offers a different approach: instead of relying only on a decision not to use opioids, opioid receptors remain pharmacologically blocked while adequate naltrexone levels are present.
Naltrexone is an opioid antagonist. It blocks the euphoric effects of opioids and, according to SAMHSA, can also reduce or suppress opioid cravings in some patients.
This does not make triggers disappear. A stressful day, familiar environment or old relationship can still activate memories and thoughts about opioids. The important difference is that medication can provide an additional barrier between the trigger and the expected opioid reward.
Lower craving pressure may make it easier to pause and use the coping strategies learned in counseling.
Rather than only trying to survive a trigger, the person can learn why it happened and develop a different response.
Medication can create support while counseling addresses thinking, habits, relationships, emotional distress and the circumstances surrounding addiction.
Long-acting formulations were developed partly to address the adherence difficulties seen with daily oral naltrexone.
Medication can work alongside trigger management, support, accountability and behavioral treatment rather than replacing them.
The protected treatment period can be used to strengthen routines, relationships and skills that will still matter when medication treatment eventually changes.
A 2025 Cochrane review evaluated 22 randomized studies involving 3,416 participants and included both injectable and implantable sustained-release naltrexone. Compared with treatment as usual, sustained-release naltrexone reduced illicit opioid use during treatment.
The review also found important uncertainties. Results were not superior across every comparison, and evidence on treatment retention, acceptability and some safety outcomes remained limited. This is why naltrexone should be selected individually rather than presented as the best treatment for every patient.
In a randomized trial involving 306 detoxified patients with opioid dependence, 52.9% of participants receiving a sustained-release naltrexone implant remained in treatment without relapse at six months, compared with 15.7% receiving oral naltrexone and 10.8% receiving placebo.
This was one specific implant, study population and treatment setting, so the result should not be assumed to apply identically to every naltrexone implant.
A free DeBinge consultation is designed to help you understand how long-acting naltrexone works, what preparation is required, what the treatment can and cannot do, and how it may fit alongside counseling and relapse-prevention planning.
You can discuss your substance-use history and ask questions before deciding whether you want to proceed to a full medical assessment.
Relapse prevention becomes stronger when these strategies operate together:
Know your triggers → prepare for cravings → stay in treatment → practise recovery skills → use medication when appropriate → stay connected with people who know your plan.
The objective is not to guarantee that you will never experience another craving. It is to make sure that a craving has fewer opportunities to become a relapse.
A relapse prevention plan is a simple written guide that tells you what puts your recovery at risk, what warning signs to watch for and what to do when those risks appear.
Everyone in recovery can benefit from having one because difficult moments rarely arrive at a convenient time. Stress, cravings, conflict, loneliness or an unexpected trigger can quickly change the way you think. A written plan means you do not have to create a solution while you are already under pressure.
A relapse prevention plan works best when it becomes part of normal life — not something you only look at when recovery is already in crisis.
Reviewing it regularly helps you notice changes earlier, remember the strategies that work for you and stay connected with the people who can help. Over time, this can make recovery more structured and reduce the number of important decisions that need to be made during moments of intense craving or emotional distress.
Keep your personal high-risk situations visible and updated.
Notice changes in thoughts, emotions and behaviour before they become more serious.
Decide in advance what you will do and who you will contact when risk increases.
Think of your relapse prevention plan as a daily recovery map. You may not need every part of it every day, but when the road becomes difficult, you already know where to turn.
The first part of your plan should answer: “When am I most likely to struggle?” A trigger becomes much easier to manage once you can see it coming.
Do not limit yourself to obvious triggers such as seeing alcohol or drugs. High-risk situations can involve a person, place, emotion, time of day, access to money, relationship conflict, boredom, exhaustion or simply being somewhere strongly associated with previous substance use.
Who tends to make thoughts about using stronger?
Where have cravings appeared before?
Stress, anger, loneliness, anxiety, boredom?
Payday, weekends, arguments, celebrations or being alone?
“My three highest-risk situations are: __________, __________ and __________.”
NIDA describes stress, substance-related cues such as people, places and moods, and exposure to substances as common triggers. AHRQ similarly recommends identifying personal life stressors and situational triggers as part of a written prevention plan.
U.S. government guidance showing what should be included in a relapse-prevention plan.
Read the AHRQ Guidance →Triggers tell you what can increase your risk. Warning signs tell you that your recovery may already be starting to change.
Your plan should therefore include the changes that normally appear before you begin seriously considering substance use.
Am I sleeping normally?
Am I withdrawing from supportive people?
Am I missing appointments or recovery activities?
Am I bargaining with myself about using?
Are they becoming more frequent or intense?
Am I hiding what I am thinking or doing?
One difficult day is not proof that relapse will happen. Look for a pattern: several changes appearing together, becoming stronger or continuing for longer than usual.
“When I notice __________, __________ or __________, I will treat this as a signal to strengthen my recovery plan.”
AHRQ describes return to substance use as a process that can begin with emotional distress, isolation, disrupted sleep and self-care, followed later by bargaining, fantasising about use or reconnecting with substance-associated people and places. :contentReference[oaicite:1]{index=1}
Do not wait for a strong craving to decide how you will respond. Create the response while your thinking is clear.
“I am experiencing a craving. I do not have to act on it.”
Move away from the person, place or situation if possible.
Avoid making an immediate decision to obtain or use a substance.
Tell someone from your support plan what is happening.
Walk, change environment, breathe, distract yourself or practise urge surfing.
The U.S. Department of Veterans Affairs teaches a practical technique called urge surfing. Rather than trying to force a craving away, you observe the physical and emotional sensations as they rise, peak and eventually change — similar to riding a wave rather than fighting against it.
The purpose is to learn that a craving can be uncomfortable without automatically becoming an action.
A short practical video demonstrating a government-supported craving-management technique.
Watch the VA Urge Surfing Video →“When a strong craving appears, my first three actions will be __________, __________ and __________.”
A support plan should contain names, not simply the instruction “ask for help.” During a difficult moment you should already know who you are going to contact.
Choose several levels of support so that your recovery does not depend on one person being available at exactly the right moment.
A trusted friend, partner, family member, sponsor or peer you can contact when cravings first increase.
Your counselor, doctor, treatment provider or recovery professional.
A recovery group, peer service, helpline or alternative contact if your first choices are unavailable.
First person: ____________________
Professional: ____________________
Backup contact: ____________________
“My cravings are getting stronger and I don’t want to manage this alone. Can you stay in contact with me while I follow my recovery plan?”
SAMHSA says peer-support workers can help people remain engaged in recovery and extend recovery support beyond the clinical setting into everyday life. :contentReference[oaicite:2]{index=2}
Learn how peer support can become part of a longer-term recovery network.
Explore SAMHSA Recovery Support →Your relapse prevention plan should also answer the question nobody wants to need: “What happens if my normal coping strategies are not enough?”
An emergency plan is not an expectation that you will fail. It is the same reason people keep a fire extinguisher in a house: preparation allows faster action when the consequences of hesitation could be serious.
CDC advises that if you are unsure whether someone is experiencing an opioid overdose, treat the situation as an overdose. Naloxone can reverse an opioid overdose and can be given by a bystander while emergency assistance is being called. :contentReference[oaicite:3]{index=3}
Keep naloxone somewhere accessible, make sure people close to you know where it is, and learn how to use it before an emergency occurs.
Do not assume that someone else will have it. An emergency plan works best when the people involved already know their role.
CDC’s step-by-step instructions for recognising and responding to a suspected opioid overdose.
Read the CDC Instructions →A short official CDC video explaining why naloxone should be available when opioid overdose risk exists.
Watch the CDC Naloxone Video →Practical federal guidance covering overdose risk, overdose-reversal medications and emergency response.
Read the SAMHSA Toolkit →
If I think I am going to return to use:
I will contact ______________________________.
My treatment/counseling contact:
____________________________________________.
If opioid exposure is possible, my naloxone is kept:
____________________________________________.
The people who know how to access it are:
____________________________________________.
The plan should move you from: “I hope I will make the right decision” to “I already know what I will do when risk increases.”
Keep the plan somewhere easy to reach, review it regularly and update it whenever you discover a new trigger, warning sign or coping strategy.
The following relapse prevention plan example shows how the ideas in this guide can be turned into a simple plan that can actually be used in everyday life. It is only a sample — your own plan should reflect your personal triggers, warning signs, treatment, support network and medical needs.
Imagine someone who has stopped using substances, is attending counseling and generally feels stable, but knows that work stress, poor sleep, payday and contact with old substance-using friends have caused problems in the past.
I want to remain healthy, rebuild trust with my family, be present for the people who depend on me and stop allowing substance use to control my decisions.
When recovery becomes difficult, I will remind myself that a craving is temporary but the consequences of returning to use may last much longer.
Especially after several difficult days or conflict at work.
When I am exhausted for several nights, my ability to cope becomes weaker.
Having additional money has previously been connected with substance use.
Contact with people I previously used substances with can bring back memories and cravings.
I will remind myself: “This is a craving. I do not have to act on it.”
I will leave the situation if it is increasing my risk.
I will not make an immediate decision to obtain or use a substance.
I will tell someone from my support plan what is happening.
I will walk, change location, eat, rest, practise breathing or urge surfing, or use another coping technique that has worked previously.
Someone I can call immediately and speak to honestly about cravings.
I will contact them if cravings continue, warning signs increase or I believe I may return to substance use.
Someone I can contact if my normal support person is unavailable.
How stressed am I? Low / Medium / High
How strong were my cravings? Low / Medium / High
Did I notice any warning signs? Yes / No
Do I need additional support tomorrow? Yes / No
I will not treat one episode of use as proof that everything I achieved in recovery has been lost.
If opioid exposure is possible, overdose safety should be included in the plan. A period without opioids can reduce tolerance, which can make returning to use particularly dangerous.
CDC provides step-by-step guidance for recognising and responding to a suspected opioid overdose.
CDC: What to Do If You Think Someone Is Overdosing →This relapse prevention plan sample should not be copied once and then forgotten. Review your own plan regularly and update it whenever you discover a new trigger, warning sign, successful coping strategy or change in your treatment.
Keep a copy somewhere easy to reach — for example on your phone — and make sure at least one trusted person understands the most important parts of it.
AHRQ recommends that relapse-prevention plans identify warning signs, emotional and situational triggers, supportive contacts and concrete coping strategies, and that plans are reviewed as circumstances and recovery needs change.
Read the AHRQ Relapse Prevention Guidance →A return to substance use is not only a threat to recovery. For people who use opioids, relapse can also become a medical emergency because the body may no longer tolerate the amount of opioid it tolerated before treatment or abstinence.
This is why overdose prevention should be part of relapse prevention planning. Reduced tolerance, unpredictable fentanyl exposure, returning to an old dose and combining several substances can all increase the danger.
Someone may remember what dose they previously used, but their body may no longer be able to tolerate that dose.
Tolerance means the body has adapted to repeated exposure to a drug. Over time, a person may require a larger amount of an opioid to produce the effect that a smaller amount once produced.
When opioid use stops, tolerance can fall. This can happen during detoxification, residential treatment, incarceration, hospitalization or any period of sustained abstinence.
The dangerous part is that memory does not lose tolerance in the same way the body does. A person may remember a previous dose as “normal” even though their respiratory system is now much more sensitive to it.
This is one reason the period after detox or treatment can require particularly careful overdose-safety planning.
One of the most dangerous assumptions after abstinence is: “I used this amount before, so I can handle it again.”
That previous dose was tolerated by a body that had adapted to repeated opioid exposure. After abstinence, the same amount can produce much stronger respiratory depression.
The person’s memory of the dose may stay the same, but their biological tolerance may have changed significantly.
FDA prescribing information for extended-release naltrexone makes this risk particularly clear: after opioid detoxification, tolerance is reduced, and previously tolerated opioid doses may cause life-threatening intoxication once opioid blockade is no longer present.
Reduced tolerance is only one part of modern overdose risk. The illegal drug supply has become increasingly unpredictable because of illegally manufactured fentanyl and other potent synthetic opioids.
Fentanyl is extremely potent and may be mixed into heroin, cocaine, methamphetamine or counterfeit tablets without the person knowing it is present.
That means somebody may believe they are returning to the same substance they used previously while actually being exposed to a very different dose or drug combination.
After abstinence, a person may have lower tolerance + an unpredictable drug supply at exactly the same time.
That combination can make a return to opioid use substantially more dangerous than the person’s previous experience suggests.
CDC reports that illegally manufactured fentanyl is commonly found in powders and counterfeit pills and may also be mixed with drugs such as heroin, cocaine and methamphetamine.
Overdose risk can rise further when several substances are used together. This is known as polysubstance use.
Some combinations are particularly dangerous because they can affect breathing, consciousness, heart rate and judgement at the same time.
Both can contribute to sedation and respiratory depression.
Combining central nervous system depressants can substantially increase overdose risk.
Additional opioids can increase respiratory depression unpredictably.
Stimulants do not cancel opioid effects and may make the overall physiological response more unpredictable.
CDC specifically warns that mixing stimulants and depressants does not “balance” their effects. One drug can mask the effects of another, making it easier to take more and increasing overdose risk.
Naltrexone takes a fundamentally different approach from emergency overdose treatment: it occupies opioid receptors before opioid exposure occurs.
Naltrexone is an opioid antagonist. While an adequate naltrexone blockade is present, opioids have much more difficulty producing their usual receptor-mediated effects. This is one reason long-acting naltrexone has been investigated not only for relapse prevention but also for its potential to reduce opioid-overdose risk.
Opioid reaches receptors and can produce euphoria, sedation and respiratory depression.
Naltrexone occupies opioid receptors and reduces or blocks the expected opioid effect while adequate blockade is maintained.
A 2012 retrospective cohort study compared more than 2,300 people treated with implant naltrexone with more than 2,100 treated with oral naltrexone.
During the first four months after treatment, opioid-overdose mortality was substantially lower in the implant group: 0.67 versus 17.22 deaths per 1,000 patient-years.
The authors concluded that implant naltrexone was associated with lower all-cause mortality and opioid-overdose mortality during that early treatment period compared with oral naltrexone.
Read the PubMed Study →Another Australian study examining hospital presentations found fewer opioid-overdose presentations following sustained-release naltrexone implant treatment.
Importantly, the study also found problems involving non-opioid sedatives, demonstrating why naltrexone should never be treated as protection against every type of overdose.
Read the Research →Naltrexone blockade is powerful, but it is not an impenetrable shield. Published cases have documented fatal opioid overdoses in people who had naltrexone implants.
A larger cohort comparing implant naltrexone, methadone and buprenorphine also found no significant overall difference in crude fatal or serious non-fatal overdose rates between the three treatment groups.
The scientifically accurate conclusion is therefore: long-acting naltrexone may substantially reduce opioid-overdose risk while an effective blockade is maintained, but it cannot guarantee that overdose will not occur.
Naltrexone treatment also creates an important safety issue that every patient and family should understand.
Because the person remains abstinent from opioids, their opioid tolerance falls. When naltrexone levels eventually decline or treatment stops, the person may therefore become sensitive to doses that were previously tolerated.
FDA labeling warns that fatal overdoses have occurred when extended-release naltrexone blockade was wearing off, after doses were missed and after treatment was discontinued. Attempts to overcome the blockade by taking very large opioid doses can also cause fatal overdose.
Never try to “break through” naltrexone blockade by taking larger opioid doses. The blockade can potentially be overcome, and attempting to do so can cause life-threatening respiratory depression or fatal overdose.
These medications have similar names but very different roles.
Used as ongoing treatment to block opioid effects and support relapse prevention.
Used during a suspected opioid overdose to rapidly reverse opioid effects and restore breathing.
People receiving naltrexone should still have access to naloxone. Current FDA guidance specifically recommends discussing or prescribing an opioid-overdose reversal agent for people receiving extended-release naltrexone.
Recovery should not only answer the question “How do I avoid returning to substance use?” It should also answer: “How do I stay alive and get help quickly if something goes wrong?”
This matters particularly in opioid recovery. After a period without opioids, tolerance can decrease. At the same time, the illegal drug supply can be unpredictable, fentanyl may be present without the person knowing, and several substances may be involved in the same overdose.
Effective overdose prevention therefore uses several layers of protection: appropriate treatment for opioid use disorder, medication when suitable, continued recovery care, naloxone access, avoiding using alone if a return to use occurs, and knowing exactly how to respond to an emergency.
Reduce the likelihood of returning to uncontrolled opioid use.
Use evidence-based treatment when clinically appropriate.
Have emergency opioid-overdose reversal medication available.
Make sure someone can respond if you become unconscious.
Do not allow treatment support to disappear when you begin feeling better.
Know the overdose signs and what to do before an emergency occurs.
Naltrexone is different from methadone and buprenorphine because it is an opioid antagonist rather than an opioid agonist. It occupies opioid receptors and reduces or blocks the effects that opioids would normally produce while an adequate level of naltrexone is present.
For a person who has completed the required opioid-free period and is medically suitable for treatment, this can add an important barrier between a moment of craving and the expected opioid effect.
Imagine that somebody in recovery unexpectedly meets an old friend associated with previous opioid use. The environmental trigger may still exist and thoughts about opioids may still appear.
Naltrexone does not erase that memory or remove the need for counseling. Instead, while an adequate blockade is maintained, the expected opioid reward is pharmacologically blocked or substantially reduced. The person’s relapse-prevention skills can then be used to deal with the trigger itself.
Opioids have much more difficulty producing their expected effects while adequate naltrexone blockade is maintained.
SAMHSA states that naltrexone can reduce or suppress opioid cravings in some patients.
Medication can operate alongside counseling, trigger management, relationships, routines and other relapse-prevention work.
Sustained formulations avoid having to make the decision to take an oral naltrexone tablet every day.
Naltrexone should never be treated as an overdose guarantee.
The opioid blockade can potentially be overcome. Taking very large opioid doses in an attempt to “break through” naltrexone can result in severe poisoning, coma or death.
There is also increased vulnerability after the blockade weakens or treatment ends. Because opioid tolerance has fallen during abstinence, an amount that was previously tolerated may become dangerous.
Used as part of ongoing treatment for opioid use disorder after an appropriate opioid-free period.
Its purpose is to block opioid effects while treatment is active.
Given during a suspected opioid overdose to rapidly reverse opioid effects, particularly dangerous respiratory depression.
Naloxone is the medication to reach for during an opioid-overdose emergency.
A person receiving naltrexone can therefore still benefit from having naloxone available. FDA prescribing information for extended-release naltrexone specifically recommends discussing access to an opioid-overdose reversal medication.
Federal guidance explaining opioid blockade, craving reduction, preparation for treatment and the situations in which overdose can still occur.
Read the SAMHSA Guidance →The objective of treatment is to prevent a return to drug use. But an overdose-prevention plan must also prepare for the possibility that a person may use despite intending not to.
This is where one simple principle can become lifesaving: if overdose risk exists, another person needs to be able to respond.
During an opioid overdose, the person may become unconscious or stop breathing. At that point they cannot administer their own naloxone, call emergency services or tell someone where they are.
Two people both experience an opioid overdose.
Person A is alone. They lose consciousness and nobody knows anything has happened.
Person B has a trusted person nearby who is not intoxicated. That person notices they cannot be awakened, gives naloxone and calls emergency services.
The drug exposure may be the same. The difference is that somebody is present to respond.
Someone can notice that breathing has slowed or the person cannot be awakened.
A bystander can administer naloxone if opioid overdose is suspected.
A bystander can contact emergency medical services while continuing to help.
CDC guidance explicitly advises people at overdose risk not to use alone. If an in-person trusted contact is unavailable, overdose-prevention services can provide telephone or video contact so help can be requested if the person becomes unresponsive.
Harm-reduction planning does not mean that relapse is acceptable or inevitable. It means recognising that a person must survive a setback in order to return to treatment.
One of the strongest ways to prevent future opioid overdose is to treat the opioid use disorder itself.
Detoxification can help someone stop opioids, but detox alone does not provide the same continuing protection as ongoing treatment. The period following detox can actually be particularly dangerous because tolerance may be substantially lower.
The medications used for opioid use disorder include methadone, buprenorphine and naltrexone. Each works differently.
Activates opioid receptors in a controlled, long-acting way that can suppress withdrawal and cravings.
Treatment retention is important because protection is strongest while people remain engaged in care.
Partially activates opioid receptors, reducing withdrawal and craving with a different pharmacological profile from full opioid agonists.
It can be prescribed in office-based settings by appropriately authorized clinicians in the United States.
Blocks opioid receptors rather than activating them.
It requires an adequate opioid-free period before initiation because giving naltrexone to a physiologically opioid-dependent patient can precipitate withdrawal.
An NIH-funded study followed 17,568 adults who survived a nonfatal opioid overdose.
During the following year, opioid-related mortality was 59% lower among people receiving methadone and 38% lower among those receiving buprenorphine compared with people who did not receive medication treatment for opioid use disorder.
The researchers could not draw a reliable mortality conclusion for naltrexone because far fewer participants received it.
Someone surviving an overdose should not simply be discharged with the instruction “don’t use again.”
The event should create an opportunity to connect the person rapidly with evidence-based treatment, naloxone and continuing support.
Recovery often becomes most vulnerable during transitions: leaving detox, finishing residential treatment, leaving hospital, coming out of custody, stopping medication or gradually reducing contact with recovery services.
These are moments when several protections can disappear together.
Continuing care is designed to prevent that gap. It may include medication management, counseling, peer support, medical follow-up, family involvement, relapse-prevention planning and practical help with housing, work or other sources of instability.
The goal is to avoid a dangerous gap between “treatment has ended” and “normal life has started again.” Recovery support should follow the person across that transition.
An opioid overdose can progress rapidly. The person may not be able to tell you what they took, how much they took or whether fentanyl was present. You do not need to know all of those answers before responding.
The person does not respond to shouting, touching or attempts to wake them.
Breathing may become very slow, irregular, shallow or stop completely.
Choking, gurgling or unusual snoring can indicate airway or breathing problems.
Lips or nails may appear blue, grey, purple or unusually pale depending on skin tone.
The person may lose muscle tone and become completely unresponsive.
Very small pupils can occur during opioid overdose, although not every sign is always present.
Administer naloxone or another approved opioid-overdose reversal medication if available.
In the United States, call 911. Tell the dispatcher that the person is unresponsive and an overdose is suspected.
Follow the emergency dispatcher’s instructions. CPR or rescue breathing may be required when normal breathing is absent.
Some overdoses, particularly those involving potent opioids such as fentanyl, may require additional naloxone according to the product instructions while emergency help is on the way.
If they are breathing but unconscious, placing them in the recovery position can help reduce the risk of choking.
Do not assume that waking up after naloxone means the emergency has ended. Remain until professional medical help arrives.
CDC guidance says that if you are unsure whether somebody is experiencing an opioid overdose, treat the situation as an overdose.
Naloxone will not harm a person if opioids are not responsible for their symptoms.
That is increasingly common. CDC reports that polysubstance exposure can occur knowingly or unknowingly, including fentanyl appearing alongside stimulants, benzodiazepines, prescription opioids or heroin.
Naloxone only reverses the opioid component of an overdose. It will not reverse every other drug that may be present.
A person believes they used cocaine but the product also contains fentanyl. They become unconscious and stop breathing normally.
Give naloxone. The person may never have intended to take an opioid, but naloxone can still reverse the fentanyl component of the overdose.
Emergency medical help is still necessary because other substances may remain active even after the opioid effect begins to reverse.
Simply owning naloxone is not enough if nobody can find it during an emergency.
CDC notes that a potential bystander was present in nearly 43% of overdose deaths in 2023. That means many overdose emergencies occur in situations where another person could potentially intervene if they have the knowledge and tools to do so.
Prevent relapse when possible. Treat opioid use disorder. Maintain medication and continuing care. Keep naloxone accessible. Avoid using alone if a return to use occurs. Respond immediately when overdose is suspected.
These strategies do not compete with recovery. They protect the opportunity to continue it.
Relapse prevention does not always depend on behavioral strategies alone. For some substance-use disorders, medication can change the biological conditions in which recovery takes place — reducing withdrawal, decreasing cravings, stabilizing opioid receptors or blocking the effects of opioids.
For opioid use disorder, the three FDA-approved medications are methadone, buprenorphine and naltrexone. They work in very different ways, which means the best option depends on the person’s current opioid use, previous treatment, medical history, preferences and recovery goals.
Medication is not a replacement for recovery. It changes some of the biological pressures that can make recovery difficult.
A person can then use counseling, relapse-prevention planning, relationships, routines and behavioral skills alongside medication.
Activates opioid receptors in a controlled, long-acting way to reduce withdrawal and craving.
Partially activates opioid receptors, reducing withdrawal and craving while having a different safety profile from full opioid agonists.
Blocks opioid receptors instead of activating them and requires an adequate opioid-free period before treatment.
Methadone has been used in opioid recovery for decades and is one of the best-established medications for opioid use disorder.
Methadone is a long-acting full opioid agonist. It activates the same general receptor system involved in opioid dependence, but when the correct dose is taken consistently under medical supervision, it can prevent withdrawal, reduce opioid cravings and reduce the effects of additional opioids.
Consider someone who wakes every morning in withdrawal and spends much of the day thinking about how to obtain heroin or fentanyl.
Without treatment, a large part of that person’s day may be controlled by the cycle: withdrawal → craving → obtaining opioids → temporary relief → withdrawal.
Appropriate methadone treatment can stabilize that cycle so the person is not repeatedly moving between intoxication and withdrawal.
Stable treatment can prevent the repeated physical withdrawal that drives continued opioid use.
Less craving can make it easier to concentrate on work, relationships and behavioral recovery.
Remaining consistently engaged with medication treatment is itself an important part of reducing risk.
Methadone has extensive evidence supporting reductions in illicit opioid use and improved retention in treatment.
Methadone is still an opioid and needs appropriate clinical management. In the United States, methadone for opioid use disorder is generally provided through a SAMHSA-certified opioid treatment program.
Learn how methadone is used in opioid-use-disorder treatment and how it fits into continuing recovery care.
Read the SAMHSA Methadone Guidance →Buprenorphine also works on opioid receptors, but it behaves differently from methadone because it is a partial opioid agonist.
It activates opioid receptors enough to reduce withdrawal and craving, but its opioid effects reach a plateau. This contributes to a different safety profile compared with full opioid agonists, although overdose is still possible, particularly when buprenorphine is combined with alcohol, benzodiazepines or other respiratory depressants.
Buprenorphine is available in several formulations, including products taken under the tongue or inside the cheek and FDA-approved extended-release injections. This flexibility can make it easier to match treatment to an individual’s needs.
Someone may repeatedly stop heroin or fentanyl for several days but return to use when withdrawal and craving become difficult.
Buprenorphine can address those biological symptoms directly rather than expecting the person to repeatedly endure withdrawal using willpower alone.
Naltrexone takes a fundamentally different approach to opioid recovery: instead of activating opioid receptors, it blocks them.
Naltrexone is an opioid antagonist. It binds to opioid receptors and blocks or substantially reduces the euphoric and sedating effects that opioids would normally produce while adequate medication levels are present.
Opioid-receptor activation can reinforce continued opioid use.
The expected euphoric and sedating opioid effects are blocked or substantially reduced while adequate blockade is present.
SAMHSA also notes that naltrexone can reduce or suppress opioid craving in some patients. It is non-opioid and does not produce opioid physical dependence.
Imagine somebody experiences a strong opioid trigger after an argument. Before treatment, the thought “opioids will immediately make this feeling go away” may have had a very powerful learned association.
With adequate naltrexone blockade, the expected opioid reward is pharmacologically interrupted. The emotional trigger still needs to be understood, but medication can provide another layer while the person applies counseling and coping strategies.
Naltrexone does not activate opioid receptors in the way methadone or buprenorphine does.
It blocks the expected effects of opioids while sufficient medication levels remain present.
Reduced craving can make behavioral relapse-prevention techniques easier for some people to apply.
Naltrexone is also an established medication option for alcohol use disorder in approved formulations.
Naltrexone cannot simply be given to someone who is currently physically dependent on opioids.
The patient must first complete an appropriate opioid-free period. Starting naltrexone too soon can precipitate severe withdrawal.
SAMHSA currently advises at least 7 days after short-acting opioids and approximately 10–14 days after long-acting opioids before naltrexone in typical circumstances, but the actual timing must be determined clinically. Transitions from methadone or buprenorphine may require particular caution.
Naltrexone is not a guarantee against overdose. Patients should never attempt to overcome the blockade by taking larger opioid doses.
Opioid tolerance also falls during abstinence. When naltrexone is wearing off, a dose is missed or treatment ends, previously tolerated opioid amounts can become dangerous or fatal.
One of the most important developments in addiction medication has been the move from medications that must be taken every day toward formulations that continue working for weeks or months.
This matters because medication only works when it is actually taken. Daily adherence can become particularly difficult during the exact moments when relapse risk is increasing.
Every day requires another decision to take the medication.
Craving increases and the person begins thinking about returning to use.
Protection can be lost at exactly the time it is needed most.
Long-acting injectable buprenorphine can maintain medication exposure without requiring a tablet or film every day. FDA currently lists extended-release buprenorphine products among approved treatments for opioid use disorder.
For someone who responds well to buprenorphine but has difficulty remembering, storing or consistently taking daily medication, a long-acting formulation may reduce some of those adherence problems.
In the United States, the FDA-approved long-acting naltrexone treatment for opioid use disorder is extended-release intramuscular naltrexone. It is administered approximately once every four weeks.
This changes one of the major limitations of oral naltrexone: once the injection has been administered, the patient does not need to make a new decision every morning about whether to take the medication.
A patient taking oral naltrexone may feel stable for several weeks. One evening a trigger appears and they begin thinking about using opioids the following day.
With oral treatment, simply stopping the tablets can eventually remove the blockade. A long-acting formulation makes that process less dependent on a daily medication decision.
Implantable sustained-release naltrexone takes the same principle further: the medication is placed under the skin and designed to release naltrexone gradually for a prolonged period.
Implant formulations have been studied in randomized trials and are used in some treatment settings internationally. However, implant products are not currently FDA-approved for opioid use disorder in the United States, and different implants may use different doses, delivery systems and durations. Evidence from one implant therefore should not automatically be assumed to apply to another.
A 2025 Cochrane review evaluated 22 randomized studies involving 3,416 participants receiving injectable or implantable sustained-release naltrexone.
Compared with treatment as usual, sustained-release naltrexone reduced illicit opioid use during treatment. It may also reduce opioid use compared with oral naltrexone.
However, the evidence was much less certain for outcomes such as treatment retention, and sustained-release naltrexone did not clearly outperform opioid-agonist treatments such as methadone or buprenorphine.
The review concluded that significant evidence gaps remain, particularly around long-term outcomes, safety and differences between individual sustained-release formulations.
| Medication | How It Works | Withdrawal / Craving | Before Starting | Long-Acting Option |
|---|---|---|---|---|
| Methadone | Full opioid agonist | Reduces withdrawal and cravings | Clinical assessment | Treatment itself is long acting, usually dosed regularly |
| Buprenorphine | Partial opioid agonist | Reduces withdrawal and cravings | Requires an appropriate initiation strategy | Yes — extended-release injections are available |
| Naltrexone | Opioid antagonist | Blocks opioid effects and may reduce craving | Requires an adequate opioid-free period | Yes — monthly injection; implants studied/used in some countries |
A return to substance use can feel frightening, disappointing or overwhelming, but what happens next may be more important than the relapse itself.
One episode of substance use does not automatically erase the progress made during recovery. The priority is to respond early, reduce immediate medical risk, reconnect with treatment and understand what allowed the return to use to happen.
Try to avoid the thought: “I have already relapsed, so everything is ruined.” That kind of all-or-nothing thinking can turn one episode into several days or weeks of continued substance use.
The sooner you respond to a relapse, the more opportunity you have to prevent a brief return to use from becoming a longer return to the previous pattern.
AHRQ recommends identifying recurrence of substance use early and intervening quickly rather than treating it as proof that treatment has failed.
Avoid automatically turning one episode into permission to continue using.
Leave the high-risk environment when possible and move somewhere where additional substance use is less accessible.
Contact somebody from your recovery plan instead of hiding what happened.
Let your counselor, clinician or treatment provider know as soon as possible.
Someone who has been abstinent for three months uses opioids after an argument. Afterwards they think:
“I’ve destroyed three months of recovery. I may as well keep using.”
That thought can become more dangerous than the original mistake.
A safer response would be: “I used once. I need to tell somebody, protect myself from overdose, contact treatment and understand what happened before I use again.”
Relapse becomes more difficult to manage when it is hidden. Reconnecting quickly with treatment gives other people the opportunity to help assess what has changed and what needs to happen next.
Depending on the situation, your treatment team may need to review medication, counseling frequency, withdrawal risk, mental health, living circumstances, exposure to triggers or whether a higher level of care is appropriate.
Tell somebody what happened so that you do not manage the next decision alone.
Explain what was used, when it happened, what led to it and whether cravings are continuing.
Medication, withdrawal, overdose risk and physical complications may require medical assessment.
A simple message can be enough:
“I returned to using today. I don’t want this to continue and I need help working out what I should do next.”
Current AHRQ guidance specifically advises treatment providers not to punish or involuntarily discharge someone simply because substance use has recurred. Instead, treatment should be reassessed and strengthened where appropriate.
Once immediate safety has been addressed, the relapse can provide information that improves the next version of your prevention plan.
Do not look only at the moment the substance was used. Work backwards through the hours or days before it happened.
A person initially believes: “I relapsed because I suddenly had a craving.”
After reviewing the previous week, they notice that they had slept poorly for four nights, missed counseling, stopped speaking to their recovery contact, received their wages and then met an old friend associated with substance use.
The relapse was not as sudden as it first appeared.
The revised plan can now include: sleep problems as an early warning sign, missed counseling as a reason to reconnect immediately, payday planning and avoiding contact with that high-risk person.
Add something concrete:
Old plan:
“I will try not to use when I am stressed.”
Improved plan:
“If I have two nights of poor sleep and my cravings increase, I will contact my
counselor, avoid being alone after work and tell my recovery contact that I am
entering a higher-risk period.”
For people returning to opioids after a period of abstinence, the relapse may be more medically dangerous than previous opioid use.
Repeated opioid exposure causes tolerance. After opioids are stopped, that tolerance can decrease. The person may still remember the amount they previously used, but their body may no longer tolerate it.
NIDA specifically identifies loss of tolerance as a reason people can be at increased risk of overdose when returning to opioid use after abstinence.
Before treatment, someone regularly used an amount of heroin they believed they could tolerate.
They then spend several weeks or months without opioids.
If they return to the amount they remember using before, their current tolerance may be much lower than their remembered dose.
The illegal opioid supply may also contain fentanyl or another unexpected substance, increasing unpredictability further.
Administer naloxone or another approved opioid-overdose reversal medication if available.
In the United States, call 911 immediately.
Follow emergency-dispatch instructions and try to keep the person breathing.
This can help reduce choking risk when appropriate.
Remain until emergency medical help arrives.
If you are unsure whether an opioid overdose is occurring, CDC advises treating the situation as an overdose.
Current clinical guidance on acting early, keeping people engaged in treatment and revising the recovery plan.
Read the AHRQ Guidance →Explains why loss of tolerance following abstinence can increase overdose risk when opioid use returns.
Read the NIDA Guidance →Practical instructions covering naloxone, emergency services, breathing and staying with the person.
Read the CDC Instructions →A relapse should trigger a response, not surrender.
Act early, tell somebody, reconnect with treatment, protect against overdose, understand what happened and make the next relapse prevention plan stronger than the one before it.
Addiction recovery does not happen in isolation. Family members, partners and other trusted people can become an important part of relapse and overdose prevention — not by controlling the person, but by helping them recognise risk earlier, stay connected with treatment and get help quickly when something changes.
Family support is most useful when everybody understands the recovery plan before a crisis occurs. That means knowing the person’s main triggers, recognising warning signs, understanding who should be contacted, knowing where naloxone is kept when opioid exposure is possible, and being able to respond calmly rather than waiting until the situation becomes an emergency.
You do not need to become your loved one’s doctor, counselor or police officer.
Your role can be much simpler: notice, communicate, support, connect and respond when necessary.
One of the most useful things a family can do is understand the person’s individual relapse pattern.
Ask the person to share the parts of their relapse prevention plan that they are comfortable sharing. You do not necessarily need every private detail. You need enough information to recognise when recovery may be becoming less stable.
Stress, particular people, certain places, payday, poor sleep, loneliness or relationship conflict may increase risk.
Isolation, missed appointments, increasing secrecy, poor sleep or talking differently about previous substance use may deserve attention.
Understand what the person has agreed to do when cravings become stronger.
Keep the counselor, treatment provider or other agreed recovery contact accessible.
Imagine someone normally attends counseling every week, speaks openly with their partner and follows a stable sleep routine.
Over two weeks they begin sleeping poorly, cancel two counseling sessions, become increasingly isolated and reconnect with an old friend associated with substance use.
None of these changes alone proves that relapse will happen. But together they represent a meaningful change from the person’s normal recovery pattern.
A family member who understands the prevention plan can raise the concern before substance use returns.
How a family raises concerns matters. Shame, anger and accusations can make someone more likely to hide what is happening rather than ask for help.
CDC specifically encourages families to reduce stigma around opioid use disorder. Treating addiction as a health condition rather than a moral failure can make it easier for a loved one to disclose difficulties and engage with treatment.
“I’ve noticed that you haven’t been sleeping and you’ve missed counseling twice. Is recovery becoming more difficult at the moment?”
“You don’t have to hide cravings from me. What does your plan say we should do when they increase?”
“Would it help if we contacted your counselor together?”
“You’re obviously going to relapse again.”
“After everything we’ve done for you, how can you still be thinking about drugs?”
“If you really wanted recovery, you wouldn’t have cravings.”
A craving is not the same as a relapse.
Someone being honest enough to say “I am struggling and thinking about using” may actually be activating their relapse prevention plan exactly as intended.
Families can encourage treatment attendance, help with transportation, remind someone about appointments when asked and support medication adherence, but treatment decisions should remain between the patient and qualified clinicians.
This is particularly important with medications for opioid use disorder. Methadone, buprenorphine and naltrexone work differently, and stopping medication simply because someone appears to be doing well can remove an important layer of recovery protection.
Accountability can help recovery. Constant surveillance can damage trust.
Families should agree in advance what accountability looks like rather than making new rules during an argument.
“If your cravings become strong, please tell me and we will contact your support person.”
“If you miss several treatment appointments, can I ask what is happening?”
“Let’s agree where naloxone will always be kept.”
Searching belongings continuously without an agreed reason.
Interrogating the person every time they leave the house.
Treating every bad mood as evidence of substance use.
The goal is to create enough openness that the person can say “I need help” before the situation becomes a crisis.
Families should decide in advance what will happen if a lapse or relapse occurs. Trying to create a plan while everybody is frightened or angry is much harder.
Determine whether the person is conscious, breathing normally and medically stable.
Immediate safety and treatment are more important than deciding who is to blame.
Encourage rapid contact with the counselor, clinician or treatment provider.
Later, examine the triggers and warning signs that appeared before the return to use.
If opioid exposure is possible, naloxone should not be known only to the person in recovery.
During an overdose, the person may become unconscious and cannot administer naloxone to themselves. This makes partners, parents, friends and other household members an important part of overdose prevention.
CDC specifically recommends that people at increased risk for opioid overdose keep naloxone available and let others know where it is. CDC also provides naloxone education specifically for family members and caregivers.
A family owns naloxone, but it is kept in the recovering person’s locked bedroom and nobody else knows where it is.
Technically the household has naloxone. Practically, it may not be available during an emergency.
A better plan is to agree on a predictable, accessible location and make sure several people know how to use it.
Families should be able to distinguish ordinary sleep from a possible opioid overdose. Warning signs may include:
The person does not respond normally to voice or attempts to wake them.
Breathing may become shallow, irregular or stop.
Unusual snoring, choking or gurgling can indicate dangerous breathing problems.
Lips, skin or nails may become blue, grey, purple or unusually pale.
If you are unsure whether opioids are responsible, CDC recommends treating the situation as an overdose. Naloxone will not harm someone simply because opioids were not the cause.
If the person uses medication as part of recovery, family members can benefit from understanding its purpose without trying to manage the medication themselves.
For example, naltrexone blocks opioid receptors while adequate medication levels are present, but it should not be treated as a guarantee that opioid overdose is impossible.
Family members should understand that attempts to overcome naltrexone blockade with large opioid doses can be extremely dangerous. They should also know that opioid tolerance may be reduced when treatment eventually wears off or ends.
Supporting someone does not mean removing every consequence of substance use. Families can be compassionate while still maintaining clear boundaries around money, violence, driving, children, substances in the home or other unsafe behaviour.
Addiction can affect an entire household. Fear of overdose, repeated crises, financial pressure and uncertainty can leave family members exhausted.
Supporting someone else’s recovery should not require ignoring your own mental or physical health. SAMHSA recommends that families consider options such as family therapy, counseling and family support groups.
Ask yourself:
What situations place the person at greatest risk?
What changes usually appear when recovery is becoming unstable?
Who should be contacted when cravings or relapse occur?
Where is it kept and who knows how to use it?
Does everyone know what to do if an overdose is suspected?
Guidance on family support, family therapy and caring for the whole household.
Read SAMHSA Family Guidance →Practical naloxone information and training resources specifically for families.
Explore CDC Naloxone Resources →Information on supporting a loved one, treatment and reducing addiction stigma.
Read CDC Recovery Guidance →Make it easier for your loved one to tell you that recovery is becoming difficult before they need to tell you that a relapse has already happened.
Combine that openness with treatment, clear boundaries, a written relapse plan and overdose preparation, and the family becomes another layer of protection around recovery.
Recovery is different for everyone. Some people need to understand their triggers better. Others need a stronger craving plan, more support, continued treatment, counseling or a conversation about medication.
Answer these 20 questions to identify the areas that may deserve the most attention in your recovery plan.
If you would like to better understand your relapse risk, how cravings can be managed, what overdose-prevention steps may be appropriate, or whether medication-supported recovery could fit your situation, you can speak with the DeBinge team.
The consultation is designed to be informational and educational, so you can ask questions and understand the available options before deciding on any next step.
Book a Free Educational ConsultationThese frequently asked questions bring together the most important practical points from this guide. Click any question to open the answer.
Relapse prevention is the process of identifying the situations, emotions, thoughts and behaviors that can increase the risk of returning to substance use and deciding in advance how you will respond.
A good relapse prevention plan usually includes your personal triggers, early warning signs, craving-management strategies, treatment plan, support contacts and an emergency plan.
The goal is not to guarantee that you will never experience another craving. It is to make sure that when risk increases, you already know what to do next.
Common triggers include stress, relationship conflict, poor sleep, anxiety, loneliness, boredom, money, certain people, places associated with previous substance use, celebrations, alcohol or other substances.
Triggers are highly individual. The most useful question is: “What consistently changes the way I think about using?”
Keeping a short trigger log can help reveal patterns that are difficult to recognise from memory alone.
Warning signs can appear before substance use returns. They may include increasing isolation, poor sleep, irritability, anxiety, missed treatment appointments, secrecy, romanticising previous substance use, stronger cravings or reconnecting with people and places associated with use.
One difficult day does not automatically mean relapse is coming. Patterns matter more than a single symptom.
Several warning signs appearing together, becoming stronger or continuing for several days should be treated as a signal to strengthen the recovery plan.
No. A craving is an urge or internal signal. It is not an instruction that you must follow.
The important skill is learning to create distance between the craving and the decision.
Changing your environment, delaying the decision, contacting support and using coping strategies such as breathing, distraction or urge surfing can help the craving change without becoming substance use.
Use a simple sequence:
If cravings continue increasing or feel difficult to control, contact your counselor or treatment provider rather than waiting for a relapse.
During intense stress or craving, decision-making can become more difficult. A written plan removes some of the need to invent a solution while you are already under pressure.
Your plan should tell you: what puts you at risk, what warning signs to watch for, what you will do, and who you will contact.
AHRQ recommends prevention plans that identify warning signs, emotional or situational triggers, support contacts and concrete coping strategies.
Review it regularly rather than waiting until a crisis.
A brief daily or weekly review can help keep your main triggers and response plan familiar. The plan should also be updated after major life changes, new triggers, changes in treatment or any return to substance use.
Recovery changes over time, so the plan should change with it.
Not necessarily. A return to substance use can indicate that the treatment or prevention plan needs to be reassessed.
Current AHRQ guidance recommends responding to recurrence of use by keeping the person engaged in treatment, identifying what changed and strengthening treatment or support where necessary rather than punishing or abandoning the person.
The useful question after relapse is: “What needs to change now?”
Act early.
Do not allow one episode of use to become a reason to continue using because you believe all previous recovery progress has been lost.
Opioid tolerance can fall during abstinence. A person may remember the amount of opioid they previously used, but their body may no longer tolerate that amount.
Returning to a previously familiar dose can therefore cause much greater respiratory depression than expected.
The risk can be increased further by fentanyl, unpredictable drug strength and combining opioids with alcohol, benzodiazepines or other substances.
The main evidence-based medications for opioid use disorder are methadone, buprenorphine and naltrexone.
Methadone is a full opioid agonist, buprenorphine is a partial opioid agonist and naltrexone is an opioid antagonist.
They work differently, so the appropriate medication depends on the person’s current opioid use, previous treatment, medical history, treatment goals and clinical assessment.
Naltrexone blocks opioid receptors rather than activating them. While adequate medication levels are present, it blocks or substantially reduces the euphoric and sedating effects of opioids.
SAMHSA also states that naltrexone can reduce or suppress opioid cravings in some patients.
Medication does not remove the need to work on triggers, stress, relationships and behavioral patterns. Instead, it can provide another biological layer alongside relapse-prevention work.
Naltrexone provides opioid-receptor blockade while adequate medication levels are present, which can reduce exposure to the expected effects of opioids.
However, it should never be described as a guarantee against overdose.
Attempting to overcome the blockade with very large opioid doses can be fatal. Overdose vulnerability can also increase after naltrexone wears off, is missed or is discontinued because opioid tolerance may have fallen.
People receiving naltrexone should still have an overdose-safety plan and access to naloxone when opioid exposure is possible.
Their names are similar, but their roles are very different.
Naltrexone is used as ongoing treatment to block opioid effects and support recovery.
Naloxone is an emergency medicine used during a suspected opioid overdose to rapidly reverse opioid effects and restore breathing.
Naloxone is the medication to use during an opioid-overdose emergency.
No. Naltrexone must not be started while a person is still physiologically dependent on opioids because it can precipitate significant withdrawal.
SAMHSA advises an opioid-free interval before starting naltrexone, but the correct timing depends on the opioid involved and the person’s clinical circumstances.
Transitions from medications such as methadone or buprenorphine require particular clinical planning. A qualified clinician should determine when naltrexone can be started safely.
One major advantage of a long-acting formulation is that it reduces the need to decide every day whether to take a tablet.
This can be important because medication adherence may become more difficult during periods of craving or increasing relapse risk.
In the United States, extended-release injectable naltrexone is FDA approved for opioid use disorder. Implantable naltrexone products are used or studied in some other settings, but their regulatory status, duration and evidence vary by product.
A long-acting formulation is therefore not automatically the best choice for everyone; suitability requires individual assessment.
Medication and counseling address different parts of recovery.
Medication may reduce withdrawal, craving or opioid effects, but counseling can help address the reasons substance use became connected with stress, relationships, trauma, emotional distress or particular environments.
Counseling also gives people an opportunity to practise coping skills before high-risk situations occur.
A useful principle is: medication can reduce pressure while counseling builds skills.
Families can help by understanding the relapse prevention plan, recognising warning signs, supporting treatment, encouraging honest conversations and knowing who to contact when risk increases.
The goal is not constant surveillance. Healthy accountability works best when expectations are agreed in advance.
Family members can also learn how to recognise an overdose and use naloxone when opioid exposure is possible.
Treat a suspected opioid overdose as a medical emergency.
In the United States, call 911. CDC advises that if you are unsure whether an opioid overdose is occurring, treat the situation as an overdose.
There is usually no single most important technique. Relapse prevention is strongest when several protections work together.
A strong plan includes:
The objective is to make recovery less dependent on one decision made during one difficult moment.
This guide draws on U.S. government clinical guidance, public-health recommendations and peer-reviewed research on relapse prevention, cravings, opioid use disorder, naltrexone and overdose prevention.
The references below allow readers, families and healthcare professionals to examine the evidence behind the practical recommendations in this article. Where evidence differs between treatments or formulations, those limitations are also included.
Current clinical guidance on identifying warning signs, emotional and situational triggers, developing a prevention plan, responding early to recurrence of use and keeping people engaged with treatment.
Agency for Healthcare Research and Quality (AHRQ). Medications for Opioid Use Disorder Playbook: Prevent and Respond to Recurrence of Use. Page last reviewed May 2026.
Read AHRQ Guidance →One of the foundational models behind modern relapse prevention. It examines high-risk situations, coping skills, cravings, expectations, self-efficacy and the behavioral processes that can precede a return to substance use.
Larimer ME, Palmer RS, Marlatt GA. Relapse Prevention: An Overview of Marlatt’s Cognitive-Behavioral Model. Alcohol Research & Health. 1999;23(2):151–160. PMID: 10890810.
Read on PubMed →A modern scientific review examining how chronic stress, trauma, adverse environments and disrupted stress responses can contribute to craving, maladaptive coping, substance use and relapse risk.
Sinha R. Stress and Substance Use Disorders: Risk, Relapse, and Treatment Outcomes. Journal of Clinical Investigation. 2024;134(16):e172883. PMID: 39145454.
Read the Scientific Review →Comprehensive SAMHSA guidance covering methadone, buprenorphine and naltrexone together with treatment, monitoring and recovery support.
Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63.
Read SAMHSA TIP 63 on NCBI →Current FDA information about the three medications approved for opioid use disorder: methadone, buprenorphine and naltrexone, including FDA-approved formulations.
U.S. Food and Drug Administration. Information About Medications for Opioid Use Disorder (MOUD).
Read FDA Guidance →The dedicated naltrexone chapter of SAMHSA TIP 63 explains opioid-receptor blockade, oral and extended-release formulations, initiation requirements, patient selection, overdose risk and treatment discontinuation.
Substance Abuse and Mental Health Services Administration. TIP 63, Chapter 3C: Naltrexone. Hosted by the National Library of Medicine.
Read the Naltrexone Chapter →CDC clinical guidance covering evidence-based medications for opioid use disorder, overdose prevention and the importance of ongoing treatment rather than detoxification alone.
Centers for Disease Control and Prevention. Opioid Use Disorder: Treating.
Read CDC Treatment Guidance →Guidance for patients, families and bystanders covering naloxone, opioid-overdose recognition and emergency response.
Centers for Disease Control and Prevention. Reverse Opioid Overdose to Prevent Death.
Read CDC Naloxone Guidance →Public-health guidance covering treatment for opioid use disorder, naloxone, overdose prevention and what to do when an overdose is suspected.
Centers for Disease Control and Prevention. Preventing Opioid Overdose.
Explore CDC Overdose Prevention →This systematic review included 22 randomized controlled trials involving 3,416 participants receiving injectable or implantable sustained-release naltrexone.
Compared with treatment as usual, sustained-release naltrexone reduced illicit opioid use during treatment. The review also identified important uncertainties around treatment retention, safety, long-term outcomes and differences between formulations.
Kornør H, Lobmaier PPK, Kunøe N. Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews. 2025; Issue 5. CD006140.
Read the Cochrane Review →A six-month randomized trial involving 306 recently detoxified patients compared a 1000 mg sustained-release naltrexone implant with oral naltrexone and placebo.
At six months, 52.9% of participants in the implant group remained in treatment without relapse compared with 15.7% receiving oral naltrexone and 10.8% receiving placebo.
Krupitsky E, et al. Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. Archives of General Psychiatry. 2012;69(9):973–981. PMID: 22945623.
Read the Study on PubMed →A retrospective Australian cohort compared mortality among 2,155 patients treated with oral naltrexone and 2,389 patients treated with implant naltrexone for problematic opioid use.
Lower mortality and opioid-overdose mortality were observed in the implant group during the early treatment period. Because this was observational research, it cannot establish that the implant alone caused the difference.
Kelty E, Hulse G. Examination of Mortality Rates in a Retrospective Cohort of Patients Treated With Oral or Implant Naltrexone for Problematic Opiate Use. Addiction. 2012. PMID: 22487087.
Read the Study on PubMed →This Western Australian study compared fatal and serious non-fatal opioid overdose among patients treated with methadone, buprenorphine or implant naltrexone.
No significant difference was observed between the three groups in crude rates of fatal or serious non-fatal opioid overdose. This is an important reminder that no medication should be presented as guaranteeing protection from overdose.
Kelty E, Hulse G. Fatal and Non-Fatal Opioid Overdose in Opioid Dependent Patients Treated With Methadone, Buprenorphine or Implant Naltrexone. International Journal of Drug Policy. 2017;46:54–60. PMID: 28609749.
Read the Study on PubMed →Results from one sustained-release naltrexone implant should not automatically be assumed to apply to every implant product.
Implant formulations may differ in dose, release profile, delivery system, duration, manufacturing and regulatory status. Research findings should therefore be interpreted in relation to the specific product and patient population studied.
In the United States, the FDA-approved long-acting naltrexone formulation for opioid use disorder is extended-release intramuscular naltrexone. Implantable formulations have a different regulatory status.
Clinical guidance covering medication treatment, counseling, recurrence prevention and continuing care.
Explore AHRQ → SAMHSA — Medications for Opioid Use DisorderSAMHSA TIP 63 guidance covering methadone, buprenorphine, naltrexone, treatment planning, counseling and recovery support.
Read SAMHSA TIP 63 on NCBI → CDC Overdose PreventionInformation about fentanyl, naloxone, overdose prevention and treatment for opioid use disorder.
Explore CDC → FDA MOUD InformationFDA information about approved medications and formulations for opioid use disorder.
Explore FDA →Medically reviewed by Dr. Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction treatment
Last medically reviewed: September 2026
View Medical Reviewer Profile →Medical evidence and treatment guidance can change. This article is educational and should not replace individualized assessment by a qualified healthcare professional.
Medically reviewed by Dr. Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction treatment
Last medically reviewed: September 2026
Ask about suitability, the medically supervised OLANI transition pathway, travel to Nassau and the year-long counselling programme.
